REG - Oxford BioDynamics - Board Changes

Oxford BiodynamicsAnnouncement

17/03/2025 07:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250317:nRSQ8074Aa&default-theme=true

RNS Number : 8074A  Oxford BioDynamics PLC  17 March 2025

 

 

 

Oxford BioDynamics Plc

("OBD" or the "Company" and, together with its subsidiaries, the "Group")

Board Changes

Oxford, UK - 17 March 2025 - Oxford BioDynamics Plc (AIM: OBD, the
Company), a precision clinical diagnostics company bringing specific and
sensitive tests to the practice of medicine based on its EpiSwitch® 3D
genomics platform, is pleased to announce the appointment of Peter Presland to
the Board as Non-Executive Director and Chair of the Company's Audit
Committee.

Peter Presland is an experienced Non-Executive Director and Chairman with 50
years' experience in business, much of that at the highest levels of
management within both public and private companies. A law graduate at King's
College, University of London, he qualified as a Chartered Accountant with
Arthur Andersen. In 1980, he joined C E Heath plc ("Heath"), a major publicly
quoted international insurance group, as Group Accountant/Treasurer and became
in 1985 the Group Finance Director. He was promoted to Heath's Group Chief
Executive in 1990, and in 1996 led the demerger of Heath's computer services
operations into a separate publicly listed company, Rebus Group plc, becoming
its Chief Executive and in 1999 its Chairman.

Since 2001, Peter has pursued a portfolio non-executive career, becoming
Chairman of a number of IT and financial services companies, including LINK,
the UK ATM network, in 2003 where he led a major corporate governance change
as well as the merger of LINK with Voca, the provider of the BACS service,
becoming Chairman of VocaLink in 2007. Among other appointments, from 2012 to
2015, he served as Chairman of the Audit & Governance Committee of East
Kent Hospitals NHS Trust, in 2017 was appointed to the board of Redx Pharma
PLC, and in 2019 was asked to become Chairman of the Governance & Finance
Committee of the Lord's Taverners, a high-profile charity.

As indicated in the announcement of the Company's preliminary results on 28
February 2025, Non-Executive Director and former Chairman Matthew Wakefield
has stepped down from the Board, with effect from today.

Iain Ross, Executive Chairman of Oxford BioDynamics, said: "I am very pleased
to welcome Peter to the OBD Board. I have seen at first hand the support and
challenge he offers in a non-executive capacity. His professional background
and extensive experience will complement the Board perfectly and, from a
governance perspective, improve the balance of independence among our
directors as a group."

"I would like again to extend my thanks to Matthew Wakefield for his service
to OBD as Non-Executive Chairman from December 2020 until my recent
appointment. Through his leadership of the Board over the last four years,
Matthew has been unstinting in his support of the Company and its Management
as well as in working to raise funds for the Company on several occasions. On
behalf of the Board, I wish him every success in his future endeavours."

-Ends-

For further details please contact:

  Oxford BioDynamics Plc                                              Tel: +44 (0)1865 518910
 Iain Ross Executive Chairman

 Paul Stockdale, CFO
 Shore Capital - Nominated Adviser and Broker                         Tel: +44 (0)20 7408 4090
 Advisory: Stephane Auton / Lucy Bowden

 Broking: Fiona Conroy
 OAK Securities - Joint Broker                                        Tel: +44 (0)20 3973 3678
 Jerry Keen / Henry Clarke / Damion Carruel
 WG Partners - Joint Broker                                           Tel: +44 (0)20 3705 9330
 David Wilson / Claes Spång / Satheesh Nadarajah / Erland Sternby
 Camarco - Financial PR                                               Tel: +44 (0)20 3757 4980
 Marc Cohen / Tilly Butcher / Fergus Young                            OBDFinancial@camarco.co.uk

 

Regulatory Disclosures (in accordance with Rule 17 and Schedule Two paragraph
(g) of the AIM Rules for Companies)

Save for the information set out below, there are no further disclosures to be
made in accordance with Rule 17 and Schedule Two paragraph (g) of the AIM
Rules for Companies in respect of the appointment of Mr Peter Eric Presland,
aged 74. Peter has no beneficial interest in the Ordinary Shares of the
Company.

Current Directorships

Mainvalley Limited

Rookhill Limited

Clausegate Limited

Redx Pharma Ltd (formerly plc)

Ashington Innovation PLC

Purepro Solutions Limited

Zeel Holdings Limited

Zeel Solutions Limited

 

Past Directorships

Beautiful Information Limited

GBR Advisory Limited

Clear Factor Limited(1)

 

(1) On 18 December 2023, FRP Advisory Trading Limited (the "Administrators")
were appointed as administrators to Clear Factor Limited ("Clear Factor").
Immediately following this appointment, the Administrators executed a
pre-packaged sale of the business and assets to Positive for consideration,
totaling £150,000. Details of the sale were circulated to creditors as part
of the Proposals, which were issued in accordance with statute. The
administration moved to dissolution of Clear Factor on 12 December 2024 and
the company was dissolved on 12 March 2025. Clear Factor had no secured or
primary preferential creditors and insufficient asset realisations to enable a
distribution to unsecured creditors. The final report of the Administrators
confirmed that no further investigations or actions were required in respect
of any potential claims against directors.

Notes to Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) is an international biotechnology company,
advancing personalized healthcare by developing and commercializing precision
clinical diagnostic tests for life-changing diseases.

Currently OBD has two commercially available products: the EpiSwitch® PSE
(https://url.avanan.click/v2/___http:/www.94percent.com/___.YXAxZTpzaG9yZWNhcDphOm86ZGFiYjhlY2EwMWM5YWYzYjdhZjZhZmExZGM4OTMyMDg6NjphZTRmOjE1ZmE3ZTA1NmFmMzlmYjIzZmFhOGU1NTc5MWI0OTdiODZmMjVmOTFlOWQ2YjBiZTM3YmNmMTMxMGYxOTcxMjI6cDpU)
 (EpiSwitch Prostate Screening test) and EpiSwitch® CiRT
(https://url.avanan.click/v2/___https:/www.mycirt.com/___.YXAxZTpzaG9yZWNhcDphOm86ZGFiYjhlY2EwMWM5YWYzYjdhZjZhZmExZGM4OTMyMDg6NjpjZGI4OjQ3ZWJmMjU3YzNhNjYzYzNiYWVjZGNlMTJjZDM5ZGZkYzBlNmQyNTc0OTdlZWU4ZGI4ODFlYzU1OWZmN2JmMWE6cDpU)
 (Checkpoint Inhibitor Response Test) blood tests. PSE boosts the predictive
accuracy of a PSA test from 55% to 94% when testing the presence or absence of
prostate cancer. CiRT is a highly accurate (85%) predictive response test to
immuno-oncology checkpoint inhibitor treatments.

The tests are based on OBD's proprietary 3D genomic biomarker platform,
EpiSwitch® which enables screening, evaluation, validation and monitoring of
biomarkers to diagnose patients or determine how individuals might respond to
a disease or treatment.

OBD's clinical smart tests have the potential to be used across a broader
range of indications, and new tests are being developed in the areas of
oncology, neurology, inflammation, hepatology and animal health.

The Group's headquarters and UK laboratories are in Oxford, UK. Its US
operations and clinical laboratory are in Maryland, USA, along with a
reference laboratory in Penang, Malaysia.

OBD is listed on the London Stock Exchange's AIM (LSE: OBD). For more
information, please visit the Company's website, www.oxfordbiodynamics.com
(https://url.avanan.click/v2/___http:/www.oxfordbiodynamics.com___.YXAxZTpzaG9yZWNhcDphOm86ZGFiYjhlY2EwMWM5YWYzYjdhZjZhZmExZGM4OTMyMDg6Njo3YmRiOmUxODM2ZWZhYmIxNjdhMjFiNTMxOThjNjE0YzMwYzg5YzA1MjI2MmYxMGY0ZTU1MzdjYzdlYzg1NDA5ZTcyOWU6cDpU)
,  X (@OxBioDynamics) or LinkedIn
(https://url.avanan.click/v2/___https:/www.linkedin.com/company/oxford-biodynamics___.YXAxZTpzaG9yZWNhcDphOm86ZGFiYjhlY2EwMWM5YWYzYjdhZjZhZmExZGM4OTMyMDg6NjozM2I4OmVmNzdkN2M0NmYxZDg3ODc0MWQ1NDEyMGQ4MjAxOWVmMTg4ZTMzNWY4MTA5NGE3NTE5ZDdlNWIwNjI5MTRhMTM6cDpU)
.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAUSVNRVOUOAAR